EYP001



NAME OF DRUG : EYP001

ALSO KNOWN AS : EYP001

LABORATORY : ENYOPHARMA

STATUS AND ADVANCEMENT

Type of drug : Non BA FXR agonist

Clinical trials advancement : Initiating Phase 2b

Estimated time to market : 112 months.

LABORATORY ABSTRACT ON THE DRUG

EYP001 which is an orally bioavailable synthetic non-steroidal, non-bile acid FXR agonist small molecule is also developed in NASH. Most Key Opinion Leaders agree that FXR agonists could become the backbone of any future NASH therapies. It has demonstrated its efficacy in a Stelic mouse model (STAMTM) with significant positive impact on most of the NASH key parameters (Fibrosis, Steatosis, Inflammation, Ballooning, triglycerides and NAS). It differentiates from other FXR agonists by a better C4/FGF19 balance with a more prolonged C4 decrease and a lower peak of FGF19 expected to generate a better efficacy/tolerability profile.

RECENT NEWS ON EYP001

2018-11-06 : ENYO Pharma announces the successful completion of phase Ib with its FXR agonist EYP001 and the start of phase II studies in two indications, NASH and HBV

SOME PUBLICATIONS RELATED WITH EYP001

December 2017 : Targeting bile acids and lipotoxicity for NASH treatment

July 2017 : Fibroblast growth factor 19, a double-edged sword

January 2017 : Mice species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15 (necessity to monitor HCC risk with FXR agonists )

February 2013 : Dual actions of fibroblast growth factor 19 on lipid metabolism

February 2012 : Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma

January 2012 : FGF19 and Cancer

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH EYP001


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE